Zasocitinib
- Generic Name
- Zasocitinib
Takeda Achieves Diversity Milestone in Phase 3 Psoriasis Trial with Zasocitinib
• Takeda's Phase 3 trial for oral psoriasis treatment zasocitinib has exceeded enrollment goals for underrepresented populations, completing recruitment six months ahead of schedule.
• The company implemented its PAVE framework (Partnering, Addressing barriers, Verifying goals, Enhancing site diversity) to improve trial inclusivity, more than doubling Hispanic enrollment and nearly doubling Black/African American participation.
• Strategic community engagement through partnerships with organizations like Alpha Phi Alpha Fraternity and specialized training on diagnosing psoriasis across different skin tones have been key to Takeda's success in diversifying clinical research.
JAK Inhibitors Pipeline Expands with 55+ Drug Candidates as Major Pharma Companies Drive Innovation
• The JAK inhibitors therapeutic landscape shows robust growth with over 50 pharmaceutical companies developing 55+ pipeline candidates across various clinical stages.
• Key drug candidates including Povorcitinib, Zasocitinib, and Ritlecitinib are advancing through late-stage clinical trials for conditions like vitiligo, psoriasis, and ulcerative colitis.
• Recent developments include promising results from Pelabresib-ruxolitinib combination therapy for myelofibrosis and expanded access initiatives by Eli Lilly for baricitinib in Africa.
JAK Inhibitors Show Promising Long-term Safety and Efficacy in Atopic Dermatitis Treatment, Yale Expert Reports
• Yale dermatology expert Dr. Christopher Bunick presents compelling data showing JAK inhibitors like upadacitinib and abrocitinib provide faster skin and itch relief compared to dupilumab in atopic dermatitis treatment.
• Six-year safety data reveals JAK inhibitors demonstrate lower rates of major cardiovascular and thromboembolic events in atopic dermatitis patients compared to the general patient population.
• Emerging research on TYK2 inhibitors, including deucravacitinib and zasocitinib, shows promise for expanding treatment options in inflammatory skin conditions.
Takeda's Oral TYK2 Inhibitor TAK-279 Shows Promising Efficacy in Psoriasis Treatment
• Takeda's TAK-279, an oral TYK2 inhibitor, demonstrates significant skin clearance in Phase 2b trials for moderate to severe plaque psoriasis.
• The study showed a dose-dependent response, with up to 68% of patients achieving PASI 75, indicating substantial improvement in skin condition.
• Takeda is advancing TAK-279 into Phase 3 trials for psoriasis and psoriatic arthritis, with ongoing Phase 2 studies for inflammatory bowel disease.
• The oral formulation of TAK-279 offers a convenient alternative to injectable biologics, potentially improving patient adherence and quality of life.
Sotyktu Meets Primary Endpoints in Phase 3 Psoriatic Arthritis Trials
• Bristol Myers Squibb's Sotyktu (deucravacitinib) demonstrated significant efficacy in two Phase 3 trials for active psoriatic arthritis (PsA).
• The POETYK PsA-1 and PsA-2 trials met their primary endpoint, showing a greater proportion of Sotyktu-treated patients achieved ACR20 response at Week 16 compared to placebo.
• Both trials also met key secondary endpoints related to PsA disease activity, with a safety profile consistent with previous studies.
• Sotyktu, a TYK2 inhibitor, could potentially become a novel oral treatment option for PsA, addressing the need for safe and effective therapies.
Takeda Highlights Late-Stage Pipeline with Potential Blockbuster Drugs
• Takeda is advancing six late-stage programs with a potential peak revenue of $10B-$20B, aiming for sustainable growth through innovative therapies.
• Phase 3 data readouts are expected in 2025 for oveporexton (TAK-861) in narcolepsy, zasocitinib (TAK-279) in psoriasis, and rusfertide (TAK-121) in polycythemia vera.
• Regulatory filings for oveporexton, zasocitinib, and rusfertide are on track for fiscal years 2025-2026, with additional filings anticipated through 2029.
• Key programs include mezagitamab (TAK-079) for immune thrombocytopenia, fazirsiran (TAK-999) for alpha-1 antitrypsin deficiency, and elritercept (TAK-226) for anemia in myelodysplastic syndromes.
Zasocitinib: AI-Designed TYK2 Inhibitor Shows Promise in Psoriasis and Psoriatic Arthritis Treatment
• Zasocitinib (TAK-279), an oral allosteric TYK2 inhibitor, leverages AI in its design for enhanced selectivity and efficacy in treating dermatological conditions.
• Phase 2b trial results demonstrate zasocitinib's consistent safety profile with no significant changes in laboratory parameters, differentiating it from other JAK inhibitors.
• Zasocitinib exhibits 1.7 million-fold greater selectivity for TYK2 over JAK1, potentially reducing off-target effects and improving therapeutic outcomes for patients.
• Ongoing phase 3 trials and investigations into other inflammatory conditions highlight zasocitinib's broad therapeutic potential and convenience due to lack of lab monitoring.
Takeda's Growth & Launch Portfolio Drives H1 2024 Revenue Increase; Full-Year Guidance Revised
• Takeda reported a 5% revenue increase in H1 2024, driven by an 18.7% growth in its Growth & Launch product portfolio, offsetting declines in VYVANSE sales.
• The company raised its full-year guidance due to strong H1 performance and updated foreign exchange assumptions, while core operating profit margin reached 30.2%.
• Takeda is actively investing in late-stage pipeline programs, including Phase 3 trials for TAK-861 (narcolepsy) and mezagitamab (IgA nephropathy).
• Despite robust performance, Takeda anticipates challenges in H2 due to accelerated generic erosion of VYVANSE and increased R&D spending.
Dermatology News Roundup: Bimzelx Expansion, Zoryve sNDA, and HS Insights
• Bimzelx gains FDA approval for active psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis, marking it as the first IL-17A/F inhibitor for four immune-mediated diseases.
• Arcutis' Zoryve foam sNDA accepted by the FDA for scalp and body psoriasis, supported by phase 2b and 3 data showing symptom improvement and safety, with a target action date set for May 2025.
• Semaglutide shows potential in reducing flare-ups and improving quality of life for hidradenitis suppurativa patients, suggesting weight loss medications could complement existing treatments.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath